Skip to main content

Scribe Therapeutics, Inc.

SCTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001853921

No open-market purchases or sales by Scribe Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q3 2026, worth $297.1M in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Scribe Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Scribe Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Scribe Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Andreessen Marc L10% Owner2,385,075IndirectJul 29, 20261
Horowitz Benjamin A10% Owner2,385,075IndirectJul 29, 20261
AH Bio Fund II, L.P.10% Owner2,385,075IndirectJul 29, 20261
AH Equity Partners Bio II, L.L.C.10% Owner2,385,075IndirectJul 29, 20261
AH Bio Fund III, L.P.10% Owner2,385,075IndirectJul 29, 20261
AH Equity Partners Bio III, L.L.C.10% Owner2,385,075IndirectJul 29, 20261
Gordon Carl LDirector1,348,825IndirectJul 29, 20262
OrbiMed Advisors LLCDirector1,348,825IndirectJul 29, 20261
OrbiMed Capital GP VIII LLCDirector1,348,825IndirectJul 29, 20261
Doudna Jennifer A10% Owner603,547Jul 29, 20261
Avoro Capital Advisors LLCDirector, 10% Owner, Other: See Remarks3,088,888IndirectJul 28, 20262
Aghazadeh BehzadDirector, 10% Owner, Other: See Remarks3,088,888IndirectJul 28, 20262
Avoro Ventures LLCDirector, Other: See Remarks3,088,888IndirectJul 28, 20262
Staahl Brett10% Owner–Jul 28, 20261
Lucas SvetlanaChief Business Officer3,000IndirectJul 27, 20261
Oakes Benjamin L.President, CEO–Jul 27, 20261
Watson James DeanDirector–Jul 27, 20261
Bleharski JoshuaDirector–Jul 27, 20261
Parrot DavidChief Financial Officer1,333IndirectJul 27, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 29, 2026 (view filing)7:09 PM ETJul 272 daysAndreessen Marc L and 5 others10% OwnerPPurchase+333.3K$15.00+$5.00M+16.2%2.39M after
Jul 29, 2026 (view filing)6:50 PM ETJul 272 daysGordon Carl LDirectorPPurchase+1.00M$15.00+$15.0M+286.7%1.35M afterDuplicate filing
Jul 29, 2026 (view filing)6:47 PM ETJul 272 daysOrbiMed Advisors LLC and 1 otherDirectorPPurchase+1.00M$15.00+$15.0M+286.7%1.35M after
Jul 28, 2026 (view filing)9:30 PM ETJul 24-284 daysAvoro Capital Advisors LLC and 2 othersDirector, 10% Owner, Other: See RemarksPPurchaseCommon Stock, par value $0.0001 per share+2.39M$15.16+$36.3M+342.8%3.09M after3 lots
Jul 27, 2026 (view filing)9:42 PM ETJul 234 daysLucas SvetlanaChief Business OfficerPPurchase+3.00K$15.00+$45.0KNew position3.00K after
Jul 27, 2026 (view filing)9:20 PM ETJul 234 daysParrot DavidChief Financial OfficerPPurchase+2.67K$15.00+$40.0KNew position1.33K after2 lots